Table 2.
Rates of at least a 20% IOP-lowering response at weeks 12 and 15 after a single administration of bimatoprost implant in patient subgroups in the phase 3 ARTEMIS studies
| Subgroup | Proportion of patients with ≥ 20% IOP lowering from baseline in the study eye (hour 0) after administration of bimatoprost implant 10 µg on day 1 | |
|---|---|---|
| Week 12 | Week 15 | |
| Subgroups by lens status | ||
| Phakic | 72.5% (208/287) | 56.1% (161/287) |
| Pseudophakic | 70.1% (61/87) | 59.8% (52/87) |
| Subgroups by baseline IOP | ||
| ≤ 25 mmHg | 71.6% (189/264) | 58.0% (153/264) |
| > 25 mmHg | 72.7% (80/110) | 54.5% (60/110) |
| Subgroups by previous treatment in study eye | ||
| Prior SLT | 75.0% (21/28) | 50.0% (14/28) |
| SLT-naïve (no prior SLT) | 71.7% (248/346) | 57.5% (199/346) |
| Use of PGA at screening | 72.5% (174/240) | 57.1% (137/240) |
| Subgroups by number of IOP-lowering medications used in study eye at screening | ||
| 0 | 67.8% (40/59) | 55.9% (33/59) |
| 1 | 70.6% (154/218) | 56.0% (122/218) |
| 2 | 76.9% (60/78) | 62.8% (49/78) |
| > 2 | 78.9% (15/19) | 47.4% (9/19) |
| Subgroups by race/ethnicity | ||
| White | 73.5% (175/238) | 58.4% (139/238) |
| Black | 76.5% (39/51) | 56.9% (29/51) |
| Hispanic | 71.1% (32/45) | 60.0% (27/45) |
| Asian or other | 57.5% (23/40) | 45.0% (18/40) |
IOP intraocular pressure, PGA prostaglandin analog, SLT selective laser trabeculoplasty